TB 10-drug DiaMOND compendium

Our goal was to use systematic drug combination data from in vitro studies to prioritize drug combinations for in vivo study. We used DiaMOND (DOI: 10.1126/sciadv.1701881) to systematically measure drug combination interactions and potencies against Mycobacterium tuberculosis (Erdman strain). This dataset includes all 1-, 2-, and 3-way combinations of a 10-drug set of antibiotics in eight different in vitro models. With these data, we demonstrated that treatment outcomes in two important preclinical mouse models could be predicted using signatures of drug interaction and potency metrics. File 1 (Data cube) includes the antibiotics, in vitro models, time points, and dose-response metrics. File 2 (IC90) includes the 90% inhibitory concentration of the 10 antibiotics in each in vitro model at the terminal time point. File 3 (Abbreviations) includes abbreviations and descriptions used in the Data cube and IC90 files. These data and more detailed descriptions of the experiments and analysis are in Larkins-Ford et al 2021.

本研究旨在利用体外（in vitro）实验获取的系统性药物组合数据，筛选可用于体内（in vivo）实验的优先候选药物组合方案。本研究使用DiaMOND（DOI: 10.1126/sciadv.1701881）系统性测定了针对结核分枝杆菌（Mycobacterium tuberculosis）厄尔德曼（Erdman）毒株的药物组合相互作用与药效强度。本数据集涵盖了10种抗生素的所有单药、两药联合及三药联合方案，共覆盖8种不同的体外模型。基于上述数据，本研究证实可通过药物相互作用特征与药效强度指标，预测两种重要的临床前小鼠模型中的治疗结局。文件1（数据立方（Data cube））包含抗生素信息、体外模型信息、实验时间点以及剂量反应（dose-response）指标。文件2（IC90，即90%抑制浓度（90% inhibitory concentration））收录了各体外模型在终末时间点下10种抗生素的90%抑制浓度数据。文件3（缩写对照表（Abbreviations））收录了数据立方与IC90文件中使用的缩写词及其释义。本数据集及实验与分析的详细描述详见Larkins-Ford等人2021年的研究成果。